Welcome to LookChem.com Sign In|Join Free
  • or
Ethanone, 1-[4-(methylsulfonyl)phenyl]-2-phenyl- is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

54551-91-6

Post Buying Request

54551-91-6 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

54551-91-6 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 54551-91-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,4,5,5 and 1 respectively; the second part has 2 digits, 9 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 54551-91:
(7*5)+(6*4)+(5*5)+(4*5)+(3*1)+(2*9)+(1*1)=126
126 % 10 = 6
So 54551-91-6 is a valid CAS Registry Number.

54551-91-6Relevant academic research and scientific papers

3D QSAR studies based in silico screening of 4,5,6-triphenyl-1,2,3,4- tetrahydropyrimidine analogs for anti-inflammatory activity

Lokwani, Deepak K.,Mokale, Santosh N.,Shinde, Devanand B.

, p. 233 - 242 (2014)

The 3D QSAR studies based on generation of common pharmacophore hypotheses (CPHs) were performed separately for the series of 1,2,3,4-tetrahydropyrimidin- 5-yl-acetic acid and 2-(4-sulfonylphenyl)pyrimidine analogs for their in-vivo anti-inflammatory acti

Emergent antibacterial activity ofN-(thiazol-2-yl)benzenesulfonamides in conjunction with cell-penetrating octaarginine

Das Mahapatra, Amarjyoti,Datta, Bhaskar,Hadianawala, Murtuza,Majhi, Sasmita,Mishra, Abhijit,Pandit, Shiny,Ratrey, Poonam

, p. 28581 - 28592 (2021/09/22)

Hybrid antimicrobials that combine the effect of two or more agents represent a promising antibacterial therapeutic strategy. In this work, we have synthesizedN-(4-(4-(methylsulfonyl)phenyl)-5-phenylthiazol-2-yl)benzenesulfonamide derivatives that combine

Design, synthesis and in vitro study of 5,6-diaryl-1,2,4-triazine-3-ylthioacetate derivatives as COX-2 and β-amyloid aggregation inhibitors

Dadashpour, Sakineh,Kucukkilinc, Tuba Tuylu,Tan, Oya Unsal,Ozadali, Keriman,Irannejad, Hamid,Emami, Saeed

, p. 179 - 187 (2015/03/14)

In order to find novel cyclooxygenase (COX)-2 inhibitors for treating inflammatory-based diseases such as Alzheimer's disease (AD), an ethyl carboxylate side chain was added to 5-(4-chlorophenyl)-6-(4-(methylsulfonyl)phenyl)-3-(methylthio)-1,2,4-triazine

Synthesis, docking simulation, biological evaluations and 3D-QSAR study of 5-Aryl-6-(4-methylsulfonyl)-3-(metylthio)-1,2,4-triazine as selective cyclooxygenase-2 inhibitors

Irannejad, Hamid,Kebriaieezadeh, Abbas,Zarghi, Afshin,Montazer-Sadegh, Farhad,Shafiee, Abbas,Assadieskandar, Amir,Amini, Mohsen

, p. 865 - 873 (2014/02/14)

A series of 5-Aryl-6-(4-methylsulfonyl)-3-(metylthio)-1,2,4-triazine derivatives were synthesized and their COX-1/COX-2 inhibitory activity as well as in vivo anti-inflammatory and analgesic effects were evaluated. All of compounds showed strong inhibitio

Structure-based design and synthesis of antiparasitic pyrrolopyrimidines targeting pteridine reductase 1

Khalaf, Abedawn I.,Huggan, Judith K.,Suckling, Colin J.,Gibson, Colin L.,Stewart, Kirsten,Giordani, Federica,Barrett, Michael P.,Wong, Pui Ee,Barrack, Keri L.,Hunter, William N.

, p. 6479 - 6494 (2014/10/16)

The treatment of Human African trypanosomiasis remains a major unmet health need in sub-Saharan Africa. Approaches involving new molecular targets are important; pteridine reductase 1 (PTR1), an enzyme that reduces dihydrobiopterin in Trypanosoma spp., has been identified as a candidate target, and it has been shown previously that substituted pyrrolo[2,3-d]pyrimidines are inhibitors of PTR1 from Trypanosoma brucei (J. Med. Chem. 2010, 53, 221-229). In this study, 61 new pyrrolo[2,3-d]pyrimidines have been prepared, designed with input from new crystal structures of 23 of these compounds complexed with PTR1, and evaluated in screens for enzyme inhibitory activity against PTR1 and in vitro antitrypanosomal activity. Eight compounds were sufficiently active in both screens to take forward to in vivo evaluation. Thus, although evidence for trypanocidal activity in a stage I disease model in mice was obtained, the compounds were too toxic to mice for further development.

Design and synthesis of new 2,4,5-triarylimidazole derivatives as selective cyclooxygenase (COX-2) inhibitors

Zarghi, A.,Arfaei, S.,Ghodsi, R.

, p. 1803 - 1810,8 (2020/07/30)

A new group of 2,4,5-triarylimidazole derivatives, possessing a methyl sulfonyl pharmacophore, were synthesized and their biological activities were evaluated for cyclooxygenase-2 (COX-2) inhibitory activity. In vitro COX-1/COX-2 structure-activity relati

Design, synthesis and biological evaluation of new (E)- and (Z)-1,2,3-triaryl-2-propen-1-ones as selective COX-2 inhibitors

Arfaie, Sara,Zarghi, Afshin

experimental part, p. 4013 - 4017 (2010/09/06)

A group of (E)-and (Z)-1,2,3-triaryl-2-propen-1-one derivatives possessing a methylsulfonyl COX-2 pharmacophore at the para position of the C-1 phenyl ring were synthesized and evaluated as selective COX-2 inhibitors. In vitro COX-1/COX-2 structure-activi

Synthesis and biological evaluation of 2-trifluoromethyl/sulfonamido-5,6-diaryl substituted imidazo[2,1-b]-1,3,4-thiadiazoles: A novel class of cyclooxygenase-2 inhibitors

Gadad, Andanappa K.,Palkar, Mahesh B.,Anand,Noolvi, Malleshappa N.,Boreddy, Thippeswamy S.,Wagwade

, p. 276 - 283 (2008/03/28)

A series of 2-trifluoromethyl/sulfonamido-5,6-diarylsubstituted imidazo[2,1-b]-1,3,4-thiadiazole derivatives 15a-j have been synthesized by the reaction of 2-amino-5-trifluoromethyl/sulfonamido-1,3,4-thiadiazoles 14a-b and appropriately substituted α-bromo-1,2-(p-substituted)diaryl-1-ethanones 13a-h. Structures of these compounds were established by IR, 1H NMR, 13C NMR, Mass, and HRMS data. The selected compounds were evaluated for their preliminary in vitro cyclooxygenase inhibitory activity against COX-2 and COX-1enzymes using colorimetric method. The compounds tested showed selective inhibitory activity toward COX-2 (80.6-49.4%) over COX-1 (30.6-8.6), amongst them compounds 15f and 15j showed appreciable COX-2 selective inhibitory activity. These compounds also exhibited significant anti-inflammatory activity (70.09-42.32%), which is comparable to that of celecoxib in the carrageenan-induced rat paw edema method.

Syntheses of 4,5-diaryl-1,2,3-thiadiazoles

Karimi, Lila,Navidpour, Latifeh,Amini, Mohsen,Shafiee, Abbas

, p. 1593 - 1600 (2007/10/03)

Reaction of thionyl chloride with semicarbazones of 1-(4- methylsulfonylphenyl)-2-(4-substituted pheny)lethanone gave 4-(4- methylsulfonylphenyl)-5-(4-substituted) pheny-1,2,3-thiadiazoles 5. Compounds 5-phenyl-4-(substitutedphenyl)-1,2,3-thiadiazoles 14 were similarly prepared. Chlorosulfonation of the latter followed by ammonia gave the desired compounds 5-(4-aminosulfonylphenyl)-4-(substituted) phenyl-1,2,3-thiadiazoles 6. Copyright Taylor & Francis Inc.

Synthesis and biological evaluation of 2-phenylpyran-4-ones: A new class of orally active cyclooxygenase-2 inhibitors

Caturla, Francisco,Jiménez, Juan-Miguel,Godessart, Núria,Amat, Mercè,Cárdenas, Alvaro,Soca, Lídia,Beleta, Jordi,Ryder, Hamish,Crespo, María I.

, p. 3874 - 3886 (2007/10/03)

A series of 2-phenylpyran-4-ones were prepared and evaluated for their ability to inhibit cyclooxygenase-2 (COX-2). Extensive structure-activity relationship work was carried out within this series, and a number of potent and selective COX-2 inhibitors were identified. Compounds having a p-methylsulfone group at the 2-phenyl ring showed the best COX-2 inhibitory activity. The introduction of a substituted phenoxy ring at position 3 enhanced both the in vitro and in vivo activity within the series. A selected group of 3-phenoxypyran-4-ones exhibited excellent activity in an experimental model of pyresis. The in vivo antiinflammatory activity of these compounds was confirmed with the evaluation of their antiarthritic and analgesic effectiveness. Moreover, their pharmacokinetic profile in rats is compatible with a once a day administration by oral route in humans. Within this novel series, compounds 21, 31, 34, and 35 have been selected for further preclinical and clinical evaluation.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 54551-91-6